Objective: To explore the clinical efficacy of positive airway pressure biphasic (BiPAP) non-invasive ventilation for treating the patients with severe pre-eclampsia combining acute heart failure (AHF).
Methods: A total of 84 patients with severe pre-eclampsia combining AHF treated in our hospital from 2008-01 to 2014-12 were retrospectively studied. The patients were divided into 2 groups: Control group, the patients received routine treatment for pre-eclampsia and AHF,n=41 and Observation group, based on routine treatment, the patients received assistant BiPAP ventilation,n=43. The changes at before and 3h after treatment of cyanosis, dyspnea, pulmonary rales, heart rate (HR), respiratory rate (RR), arterial oxygen saturation (SaO2), arterial partial pressure of oxygen (PaO2), arterial carbon dioxide partial pressure (PaCO2), pH value and plasma levels of BNP were compared between 2 groups.
Results:①Comparison of before vs after treatment in both groups: HR (times/min) in Control group (90±8 vs 110±14) and Observation group (80±6 vs 112±12); RR (times/min) in Control group (24±5 vs 33±8) and Observation group (18±4 vs 35±7); PaCO2 (mmHg) in Control group (41.3±4.3 vs 48.4±5.6) and Observation group (29.7±5.4 vs 47.8±3.9); BNP (ng/L) in Control group (87.50±8.00 vs 133.00±8.00) and Observation group (69.50±8.30 vs 138.00±6.92); SaO2 (%) in Control group (93.0±3.7 vs 80.5±4.7) and Observation group (97.1±3.4 vs 81.2±4.2); PaO2 (mmHg) in Control group (80.3±5.8 vs 80.5±4.7) and Observation group (89.1±6.2 vs 53.2±5.4), allP<0.05.②After treatment, compared with Control group, Observation group presented obviously decreased HR, RR, PaCO2 and BNP; signiifcantly increased SaO2 and PaO2, allP<0.05. PH was similar between 2 groups,P>0.05.
Conclusion: Assistant BiPAP ventilation may treat the patients with severe pre-eclampsia combining AHF, it could improve HF symptom and hypoxia. The clinical signiifcance should be conifrmed by further investigation.

Objective To understand the laboratory testing current situation of ABO hemolytic disease of the newborn(ABO-HDN)in Chizhou area,and to analyze the test results of serological three indexes tests in order to provide the basis for clinical diag-nosis.Methods The ABO blood group identification and serological three indexes tests(direct antiglobulin test,free antibody test, antibody release test)were performed by using microcolumn gel method.Results A,B,O and AB blood groups were 29.13%, 31.09%,37.82% and 1.96%;the total positive rate of ABO-HDN was 22.41%(80/357),the positive rates of ABO-HDN in A and B blood groups were 38.46% (40/104)and 36.04% (40/111 )respectively;the occurrence rate of ABO-HDN had no statistical difference between blood group A and B (P >0.05);the positive rates of the direct antiglobulin test,free antibody test and antibody release test were 1.96%(7/357),4.76%(17/357)and 22.41%(80/357)respectively.Conclusion The serological three indexes tests are the main basis for the diagnosis of ABO-HDN,the antibody release test shows the highest positive rate.If clinically consid-ering HDN,the newborns should conduct the ABO-HDN screening as early as possible for clarifying the diagnosis and performing the early treatment.